470 related articles for article (PubMed ID: 34687063)
1. COVID-19 Vaccine Response in People with Multiple Sclerosis.
Tallantyre EC; Vickaryous N; Anderson V; Asardag AN; Baker D; Bestwick J; Bramhall K; Chance R; Evangelou N; George K; Giovannoni G; Godkin A; Grant L; Harding KE; Hibbert A; Ingram G; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Schmierer K; Scurr MJ; Shah SN; Simmons J; Upcott M; Willis M; Jolles S; Dobson R
Ann Neurol; 2022 Jan; 91(1):89-100. PubMed ID: 34687063
[TBL] [Abstract][Full Text] [Related]
2. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
Front Immunol; 2021; 12():781843. PubMed ID: 34956211
[TBL] [Abstract][Full Text] [Related]
3. A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies.
Stoll S; Desai S; Levit E
Mult Scler Relat Disord; 2023 Mar; 71():104574. PubMed ID: 36827874
[TBL] [Abstract][Full Text] [Related]
4. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.
Tallantyre EC; Scurr MJ; Vickaryous N; Richards A; Anderson V; Baker D; Chance R; Evangelou N; George K; Giovannoni G; Harding KE; Hibbert A; Ingram G; Jolles S; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Rios F; Schmierer K; Willis M; Godkin A; Dobson R
Mult Scler Relat Disord; 2022 Aug; 64():103937. PubMed ID: 35700625
[TBL] [Abstract][Full Text] [Related]
5. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
6. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
[TBL] [Abstract][Full Text] [Related]
7. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Maniscalco GT; Liotti A; Ferrara AL; Prestipino E; Salvatore S; Di Battista ME; Moreggia O; Di Giulio Cesare D; Vastano R; Belardo M; Napolitano M; Ranieri A; Longo K; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Dec; 68():104371. PubMed ID: 36544318
[TBL] [Abstract][Full Text] [Related]
8. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
[TBL] [Abstract][Full Text] [Related]
9. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
10. Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?
Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
Clin Exp Immunol; 2022 May; 207(3):263-271. PubMed ID: 35553629
[TBL] [Abstract][Full Text] [Related]
11. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
12. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser T; Otto F; O'Sullivan C; Hitzl W; Pilz G; Harrer A; Trinka E; Wipfler P
Mult Scler Relat Disord; 2022 Mar; 59():103560. PubMed ID: 35093840
[TBL] [Abstract][Full Text] [Related]
13. B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patients.
Asplund Högelin K; Ruffin N; Pin E; Hober S; Nilsson P; Starvaggi Cucuzza C; Khademi M; Olsson T; Piehl F; Al Nimer F
Eur J Neurol; 2022 Nov; 29(11):3317-3328. PubMed ID: 35808856
[TBL] [Abstract][Full Text] [Related]
14. Effects of MS disease-modifying therapies on responses to vaccinations: A review.
Ciotti JR; Valtcheva MV; Cross AH
Mult Scler Relat Disord; 2020 Oct; 45():102439. PubMed ID: 32769063
[TBL] [Abstract][Full Text] [Related]
15. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.
Wallach AI; Schiebel M; Picone MA
Mult Scler Relat Disord; 2022 Jul; 63():103856. PubMed ID: 35636275
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
[TBL] [Abstract][Full Text] [Related]
17. Comparing humoral immune response to SARS-CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study.
Bsteh G; Hegen H; Traxler G; Krajnc N; Leutmezer F; Di Pauli F; Kornek B; Rommer P; Zulehner G; Dürauer S; Bauer A; Kratzwald S; Klotz S; Winklehner M; Deisenhammer F; Guger M; Höftberger R; Berger T
Eur J Neurol; 2022 May; 29(5):1538-1544. PubMed ID: 35102646
[TBL] [Abstract][Full Text] [Related]
18. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
Capone F; Lucchini M; Ferraro E; Bianco A; Rossi M; Cicia A; Cortese A; Cruciani A; De Arcangelis V; De Giglio L; Motolese F; Sancetta B; Mirabella M; Di Lazzaro V
Neurotherapeutics; 2022 Jan; 19(1):325-333. PubMed ID: 34859382
[TBL] [Abstract][Full Text] [Related]
20. Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis.
Hamzavi SS; Bahrololoom R; Saeb S; Marandi NH; Hosseini M; Hesam Abadi AK; Jamalidoust M
BMC Immunol; 2024 Jun; 25(1):35. PubMed ID: 38898409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
